Diabetes Recalls: Separate HbA1c Testing, Foot Review and Clinical Follow-Up
Build diabetes recall tasks from the current individual plan, preserving test dates, foot-risk review and result assessment without a universal 90-day timer.
Anaemia follow-up should connect the assessed cause, actual treatment access and start date, symptoms and comparable laboratory results to an individual clinician-written review plan. Haemoglobin, reticulocyte results and ferritin answer different questions. Do not assume every low haemoglobin value is nutritional iron deficiency, or apply the same four-week and three-month timetable to all women and adolescents.
Indian primary-care clinics coordinating anaemia assessment and follow-through for women and adolescents, including public-programme referrals and outside laboratory results.
An anaemia register should not begin by labelling every person 'iron deficient'. The clinician needs to assess the relevant cause and context, including information that may point beyond nutritional deficiency. A reminder system should preserve that assessment rather than replace it.
WHO's March 2024 haemoglobin guideline addresses measurement and interpretation across populations. A recorded haemoglobin concentration needs its unit, source and relevant patient context; it does not by itself establish the cause or an appropriate treatment regimen.
Keep age and relevant physiological circumstances accurate, and allow an appropriate private clinical history. Sensitive information should not have to be disclosed to an accompanying family member or at the reception counter merely to complete a recall form.
Record the clinical purpose of the next review: assessing response, resolving an uncertain cause, checking a treatment difficulty or completing a referral. These purposes may need different information and timing.
New or worsening symptoms should be routed through the appropriate clinical pathway. A future routine test date does not establish that a current concern can safely wait.
In an official reply dated 11 August 2026, MoHFW described the Anemia Mukt Bharat Abhiyaan guidelines released on 29 June 2026, the move to a 7×7×7 framework and a Test, Treat, Talk and Track approach. The account also distinguishes nutritional and non-nutritional anaemia.
Some older official pages still describe the previous 6×6×6 framework. A recently updated website footer is not sufficient evidence that every paragraph reflects the newer programme. Record which document and version supports the particular statement.
The 2026 announcement supports an emphasis on tracking treatment, referrals and follow-up. It does not establish that every local facility has implemented every portal or that a private clinic is automatically connected to those systems.
Where a patient receives care through a school, public facility or maternal-health service, reconcile the actual dated plan and records rather than create a competing schedule. The clinical team should resolve conflicting instructions.
This guide does not reproduce programme dose tables or assume that prophylaxis, treatment and management of non-response are interchangeable. Use the current applicable clinical protocol and qualified judgement for those decisions.
Source: MoHFW/PIB: Anemia Mukt Bharat Abhiyaan implementation, 11 August 2026
A prescription issued on 1 October does not prove the patient obtained or started it that day. Cost, stock, travel or uncertainty about instructions may delay access. Record the actual account and distinguish it from a verified dispensing event.
A laboratory result has its own specimen date, reporting date and date received by the clinic. The interpretation of a trend should use the relevant observation chronology, not simply the order in which PDFs were uploaded.
Ferritin concerns iron-status assessment and is influenced by inflammation; WHO's 2020 technical brief explains the importance of that context. Haemoglobin and ferritin are not interchangeable markers, and an increased value should not automatically trigger 'stores replenished' or treatment stopped.
If a reticulocyte result is part of the clinician's plan, retain its measurement and context separately. Do not order it automatically for every patient or treat a missing result as evidence that no response occurred.
Use an evidence record like the table below to make the clinical question visible.
On a narrow screen, scroll the table horizontally to read all columns.
| Record | Details to preserve | Shortcut to avoid |
|---|---|---|
| Assessed cause | Working diagnosis, supporting evidence and uncertainty | Assuming all anaemia is nutritional iron deficiency |
| Treatment access | Actual product/plan source, dispensing or reported access and barriers | Treating prescription date as confirmed start |
| Use and tolerance | Patient's account, interruption and concerns for review | Inferring use from an issued prescription |
| Laboratory observation | Specimen date, test, value, unit, method/source and context | Comparing unnormalised units or upload dates |
| Response interpretation | Responsible clinician's assessment against the individual plan | Declaring adequate response from one arithmetic change |
| Next step | Review, further assessment or referral with an owner | Resetting a fixed timer when a message is sent |
Source: WHO: Serum ferritin concentrations for assessing iron status, technical brief (2020)
In an original fictional record, a prescription is issued on 1 October and the patient reports starting the agreed treatment on 8 October. A subsequent specimen is collected on 22 October. That is 21 days after the prescription but only 14 days after the reported start.
The distinction matters when the clinician assesses the sequence. Do not conceal the access delay or describe the patient as having completed three weeks of treatment from the prescription date alone.
Suppose the earlier haemoglobin is recorded as 9.8 g/dL and the later laboratory uses 108 g/L. Since 1 g/dL equals 10 g/L, the later value is 10.8 g/dL. The numerical increase is 1.0 g/dL, equivalent to 10 g/L.
These invented values illustrate dates and unit conversion. They do not establish the severity, cause, adequacy of response or expected rate of improvement for a particular person. The clinician must consider the whole record and measurement context.
If the two tests used different methods or relevant circumstances changed, retain that information. A graph should show the original units and sources as well as any correctly converted display, with corrections attributable.
Ask what made the plan difficult: obtaining the treatment, understanding instructions, adverse effects, daily routines or another concern. Use the response to arrange qualified review rather than automatically extend the same prescription or label the person non-adherent.
If response is uncertain or not as expected, the clinician may need to revisit the cause, use, access, measurements or other factors. The system should support that inquiry without generating an automatic dose increase or a universal ferritin retest.
Reconcile outside care and school or public-service records where relevant and authorised. A family may be navigating several sources of advice; a clear current plan reduces contradictory instructions.
Assign result review and any referral to a named responsible person. A sample collected or report received does not finish the task if nobody has interpreted it and communicated the next step.
Explain the agreed plan in a usable format and confirm the patient's understanding. Follow-up timing should reflect the clinician's assessment of the cause, treatment and current findings, including what to do if a concern arises sooner.
In the fictional timeline, treatment is prescribed on 1 October, reportedly started on 8 October and followed by a specimen on 22 October. The later Hb of 108 g/L equals 10.8 g/dL, a 1.0 g/dL rise from 9.8. The timeline and conversion are evidence for review, not a promised response or diagnostic rule.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
No. The cause needs clinical assessment. Preserve the relevant evidence and uncertainty rather than assign one diagnosis from the haemoglobin value alone.
No. Testing and review should follow the individual's cause, treatment, circumstances and clinician plan. The tests answer different questions.
A prescription may be obtained or started later. That changes the chronology available for interpreting response and can reveal an access problem needing help.
They are equivalent concentrations because 1 g/dL equals 10 g/L. Keep the original units and source, and do not compare raw numbers as though their units were the same.
It notes MoHFW's August 2026 account of the Anemia Mukt Bharat Abhiyaan update released in June 2026. The announcement is not a substitute for the applicable clinical protocol or evidence of implementation in every local facility.
Updated on . Original anaemia record and follow-up analysis using WHO guidance and a dated Indian programme update. It does not set diagnostic cutoffs, prescribe iron or define a universal response-testing schedule. No independent clinical or legal review is claimed.
Population and measurement context matter; this article does not supply diagnostic cutoffs or a treatment schedule.
WHO technical brief based on its 2020 ferritin guideline; inflammation affects interpretation, and ferritin is not interchangeable with haemoglobin.
Official account of the 2026 programme update and Test, Treat, Talk and Track approach; not evidence that every local portal or service is implemented.
Build diabetes recall tasks from the current individual plan, preserving test dates, foot-risk review and result assessment without a universal 90-day timer.
Track referral decisions, appointments, specialist reports and clinical follow-through using a reconciled register, with ownership of unresolved cases.
Measure recall completion with fixed cohorts, task-specific evidence, clear denominators and workload checks, including a reconciled original example.
Enter the fictional prescription/start/specimen timeline and mixed-unit Hb results. Verify source preservation, a separate clinical interpretation and ownership of any access problem or referral.
Request a clinic demo